Akademik Veri Yönetim Sistemi
ESCV 2023 25o Annual Conference of the European Society for Clinical Virology , Milan, İtalya, 30 Ağustos - 02 Eylül 2023, ss.190
BACKGROUND-AIM
SARS-CoV-2 infection may lead to different clinical manifestations and chronic outcomes in healthy and immunosuppressed
individuals.People who are immunosuppressed are thought to spread SARS-CoV-2 longer, increase the duration of viral
transmission and act as a reservoir for potential mutations.A better understanding of prolonged PCR positivity in this patient group
is very important both from a therapeutic and public health perspective.The aim of our study is to examine the effect of
immunosuppressive conditions on prolonged PCR positivity in patients diagnosed with COVID-19.
METHODS
The clinical data, SARS-CoV-2 PCR test results, viral load values of 42 patients from the Adult Hematology and Bone Marrow
Departments who had SARS-CoV-2 PCR positivity for more than 14 days were included in our study.The samples of these patients
who came to our laboratory were studied using the real time PCR method.
RESULTS
Our study included 42 patients 19(%45,2) male and 23(%54,7) female, between the ages of 21 and 93.Except for one
patient(thalassemia majör) the other patients(such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia)
had a diagnosis of hematological malignancy.All patients diagnosed with malignancy(97.6%) were receiving immunosuppressive
therapy.About half of the patients(%45,2) included in our study had received a stem cell transplant.Patients have prolonged
COVID-19 positivity ranging from 14 to 78 days.The CT(Cycle Threshold)values of SARS-CoV-2 PCR tests of the patients ranged from
10 to 34.
CONCLUSIONS
In our study it was observed that patients with COVID-19 positivity for more than 1 month had more severe symptoms at the time
of admission to the hospital.In addition, it was determined that there were more stem cell transplant patients in this group
compared to the patient group with prolonged COVID-19 positivity for 14-30 days.The immunosuppressive patient group is at risk
for persistent PCR positivity migrating radiographic findings respiratory symptoms and systemic symptoms.In this group especially
in patients with hematological malignancies, immunosuppression caused by the primary disease as well as myelosuppression and
lymphopenia caused by the treatments given are thought to adversely affect the prognosis of COVID-19.